613 related articles for article (PubMed ID: 16944963)
1. Pharmacokinetic drug interaction profiles of proton pump inhibitors.
Blume H; Donath F; Warnke A; Schug BS
Drug Saf; 2006; 29(9):769-84. PubMed ID: 16944963
[TBL] [Abstract][Full Text] [Related]
2. Review article: drug interactions with agents used to treat acid-related diseases.
Humphries TJ; Merritt GJ
Aliment Pharmacol Ther; 1999 Aug; 13 Suppl 3():18-26. PubMed ID: 10491725
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
Andersson T
Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update.
Wedemeyer RS; Blume H
Drug Saf; 2014 Apr; 37(4):201-11. PubMed ID: 24550106
[TBL] [Abstract][Full Text] [Related]
5. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
de Korwin JD; Ducrotté P; Vallot T
Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.
Robinson M; Horn J
Drugs; 2003; 63(24):2739-54. PubMed ID: 14664653
[TBL] [Abstract][Full Text] [Related]
7. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
8. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
Meyer UA
Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of proton pump inhibitors in children.
Litalien C; Théorêt Y; Faure C
Clin Pharmacokinet; 2005; 44(5):441-66. PubMed ID: 15871633
[TBL] [Abstract][Full Text] [Related]
10. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
Pauli-Magnus C; Rekersbrink S; Klotz U; Fromm MF
Naunyn Schmiedebergs Arch Pharmacol; 2001 Dec; 364(6):551-7. PubMed ID: 11770010
[TBL] [Abstract][Full Text] [Related]
11. [Clinical pharmacological aspects of the proton pump inhibitor therapy: importance of pharmacogenetic differences in the clinical practice].
Mullner K; Molnar B; Tulassay Z
Orv Hetil; 2007 Mar; 148(12):543-51. PubMed ID: 17444020
[TBL] [Abstract][Full Text] [Related]
12. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.
Robinson M
Eur J Gastroenterol Hepatol; 2001 May; 13 Suppl 1():S43-7. PubMed ID: 11430508
[TBL] [Abstract][Full Text] [Related]
13. Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors.
Thjodleifsson B
Drugs Aging; 2002; 19(12):911-27. PubMed ID: 12495367
[TBL] [Abstract][Full Text] [Related]
14. Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole.
Ishizaki T; Horai Y
Aliment Pharmacol Ther; 1999 Aug; 13 Suppl 3():27-36. PubMed ID: 10491726
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
[TBL] [Abstract][Full Text] [Related]
16. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
[TBL] [Abstract][Full Text] [Related]
17. Stereoselective disposition of proton pump inhibitors.
Andersson T; Weidolf L
Clin Drug Investig; 2008; 28(5):263-79. PubMed ID: 18407713
[TBL] [Abstract][Full Text] [Related]
18. [Protonic pump inhibitors in kidney transplant patients: efficacy and safety].
Cianciolo G; Feliciangeli G; Comai G; Stefoni S
Minerva Urol Nefrol; 2007 Jun; 59(2):207-15. PubMed ID: 17571057
[TBL] [Abstract][Full Text] [Related]
19. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
[TBL] [Abstract][Full Text] [Related]
20. [Interaction between clopidogrel and proton pump inhibitors].
Harmsze AM; de Boer A; Boot H; Deneer VH; Heringa M; Mol PG; Schalekamp T; Verduijn MM; Verheugt FW; le Comte M
Ned Tijdschr Geneeskd; 2011; 155(28):A2442. PubMed ID: 21771377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
